Genmab A/S (NASDAQ:GMAB) Sets New 12-Month Low - Time to Sell?

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $22.39 and last traded at $22.41, with a volume of 44298 shares traded. The stock had previously closed at $22.78.

Analysts Set New Price Targets

GMAB has been the subject of several recent research reports. Morgan Stanley reiterated an "equal weight" rating and set a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 11th. Royal Bank of Canada upgraded Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. JPMorgan Chase & Co. restated a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Truist Financial dropped their price target on Genmab A/S from $53.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday, September 9th. Finally, BTIG Research upped their price target on Genmab A/S from $46.00 to $47.00 and gave the company a "buy" rating in a research report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Genmab A/S presently has a consensus rating of "Moderate Buy" and an average price target of $45.20.

Genmab A/S Trading Down 0.0 %

The business has a fifty day moving average of $25.58 and a 200-day moving average of $26.96. The firm has a market cap of $15.06 billion, a PE ratio of 18.98, a PEG ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). The company had revenue of $779.50 million for the quarter, compared to analysts' expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. On average, equities analysts forecast that Genmab A/S will post 1.27 EPS for the current year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. raised its holdings in shares of Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock valued at $28,000 after acquiring an additional 544 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company's stock valued at $34,000 after acquiring an additional 749 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Genmab A/S in the 1st quarter valued at about $43,000. Blue Trust Inc. raised its holdings in shares of Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock valued at $108,000 after acquiring an additional 3,880 shares in the last quarter. Finally, Headlands Technologies LLC raised its holdings in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company's stock valued at $129,000 after acquiring an additional 4,853 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.